A series of newly planned reforms are designed to entice companies to start early trials in the U.S. rather than overseas.
HHS, responding to China’s rise, moves to fast-track early drug research Read More »
Hay viajes que se recuerdan por los monumentos visitados y otros que permanecen en la memoria por las sensaciones que dejan. Castilla y León pertenece a esa segunda categoría. La comunidad autónoma más extensa de España reúne espacios naturales, pu …
Ideas para una escapada diferente entre paisajes, estrellas y buena mesa Read More »
The letter to the CMS from Democrats is the latest salvo from lawmakers concerned that WISeR is delaying care to Medicare beneficiaries.
Democrats push for more data on Medicare AI prior authorization pilot Read More »
Pocas experiencias en el mundo logran combinar historia, paisaje y lujo de una manera tan natural como los Cruceros Nilo. Navegar por las aguas del río más largo del planeta es, para muchos viajeros, la puerta de entrada a un país que parece detenido en el tiempo: templos milena …
Cruceros por el Nilo: La Forma Más Mágica de Descubrir Egipto Read More »
Novartis and Antares Therapeutics are shooting for the stars, launching a joint mission to develop small molecule oncology therapies.
Novartis, Antares stars align in cancer deal that could top $1.9B Read More »
The FDA has so far secured 600 new hires and is looking for 1,600 more as interim leadership at the agency looks to rebuild the workforce and morale after more than a year of intense attrition.
FDA hiring 2,200 people to staff up after last year’s DOGE cuts Read More »
A new report from RBC Capital Markets lists Biotechnology Innovation Organization chief executive John Crowley and military physician Heidi Overton as potential candidates for the role of FDA commissioner—as is the agency’s current acting leader, top food regulator Kyle Diamantas.
BIO CEO Crowley, DOD doctor Overton are top candidates for FDA commissioner: RBC Read More »
A few short days after announcing an FDA pivot on a separate asset, REGENXBIO is planning to test the agency’s apparent newfound rare disease outlook on another late-stage gene therapy.
REGENXBIO bets on FDA flexibility with filing plans for Duchenne gene therapy Read More »
Lilly has already spent more than $25 billion in potential business development commitments this year, including the $6.3 billion buyout of Centessa Pharmaceuticals that closed today.
Lilly deepens relationship with China’s Abbisko for $1.9B biobucks Read More »
The combined business entity with Boundless Bio, which will carry Serapha Bio’s name and fold in Boundless Bio, will focus on the development of a gene editor for alpha-1 antitrypsin deficiency.
Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China Read More »
